11 December 2025 Israeli drug maker bows to FTC pressure, removing scores of “improperly listed” patents in boon for generic manufacturers.
9 December 2025
9 December 2025
9 December 2025
8 December 2025
8 December 2025
Latest Features
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Latest Conference Videos
Americas
Brazil’s pharmaceutical IP landscape is shifting fast, and Juliana Neves of Licks unpacks how new reforms, guidelines, and rulings are resetting the strategic ground rules for innovators.
Unified Patent Court
Powell Gilbert experts share insights on how the Unified Patent Court is taking shape after two years in operation, in this session from LSPN.
Americas
This LSPN panel brings together experts from Troutman Pepper Locke, Sauvegarder Investment Management, Beam Therapeutics, Editas Med, and Takeda to explore the expanding role of IP lawyers in the life sciences industry.
Americas
Jennifer Che of Eagle IP explores key IP challenges in China and offers practical strategies to address them, covering topics such as AI, patent linkage and export controls in this LSPN session.
More News
5 December 2025 A Finnish wearable fitness gadget company has lost its bid to overturn the invalidation of a key patent, with the US Federal Circuit affirming it is abstract under Alice.
4 December 2025 The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.
3 December 2025 The appeals court reversed a jury verdict, finding the antibody-drug conjugate patent lacked adequate written description and enablement support from its priority application.
3 December 2025 Firm adds ex-DLA Piper litigator, who brings “deep technical experience” and “a proven track record” in complex patent and trade secrets cases.
3 December 2025 The firm has hired a former chemical engineer with clients in aviation, medical devices, and industrial manufacturing, who also led Kilpatrick’s patent best practices committee.
2 December 2025 The move could unlock billions in life sciences collaborations and position the UK to rival the US and China. But turning a famously conservative, patient-safety-first institution into a commercially savvy innovation hub will be no small feat.
1 December 2025 The Paris Local Division says Merz ran out of time to stop Viatris' multiple sclerosis generic, clarifying the court’s urgency standards in the process.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox